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Abstract
Background: Enthesitis is one of the psoriatic arthritis (PsA) domains. Patients with enthesitis are associated with
worse outcomes than those without enthesitis. The effect of secukinumab on the resolution of enthesitis in patients
with PsA was explored using pooled data from the FUTURE 2 and 3 studies.
Method: Assessments of enthesitis through week 104 used the Leeds Enthesitis Index. These post hoc analyses
included resolution of enthesitis count (EC = 0), median time to first resolution of enthesitis (Kaplan-Meϊer estimate),
and shift analysis (as observed) of baseline EC (1, 2, or 3–6) to full resolution (FR), stable (similar or reduction of EC),
or worse (EC > baseline). Efficacy outcomes (ACR, PASI, HAQ-DI, SF-36 PCS, and DAS28-CRP) were assessed in
patients with or without baseline enthesitis. Results are reported for secukinumab 300 and 150 mg in the overall
population and by prior TNFi treatment.
Results: A total of 65% (466/712) of patients had baseline enthesitis. In the overall population, FR was achieved as
early as week 16 in 65% (300 mg) and 56% (150 mg) versus 44% (placebo) patients, with further improvements to
91% (300 mg) and 88% (150 mg) at week 104. The majority (89%) of patients without enthesitis at baseline
maintained this status at week 104. Median days to resolution of EC were shorter with secukinumab 300 and 150
mg versus placebo (57 and 85 vs 167 days, respectively). In patients with EC of 1 or 2, shift analysis from baseline to
week 24 showed that more patients achieved FR with secukinumab 300 mg and 150 mg versus placebo, whereas
no difference between secukinumab and placebo was shown in the more severe patients with EC of 3–6. Increases
in proportions of patients with FR were observed with secukinumab irrespective of the severity of EC from baseline
to week 104. Improvements in efficacy outcomes were similar in patients with or without enthesitis treated with
secukinumab 300 mg.
Conclusion: Secukinumab provided early and sustained resolution of enthesitis in patients with PsA over 2 years.
Secukinumab 300 mg provided higher resolution than 150 mg in patients with more severe baseline EC and
showed similar overall efficacy in patients with or without enthesitis.
Trial registration: FUTURE 2: ClinicalTrials.gov, NCT01752634 (date of study registration: December 19, 2012), and
EudraCT, 2012-004439-22 (date of study registration: December 12, 2012)
FUTURE 3: ClinicalTrials.gov, NCT01989468 (date of study registration: November 21, 2013), and EudraCT, 2013-004
002-25 (date of study registration: December 17, 2013)
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Background
Psoriatic arthritis (PsA) is a chronic inflammatory disorder,
associated with musculoskeletal manifestations (peripheral
arthritis, spondylitis, enthesitis, and dactylitis) and extra-
musculoskeletal manifestations (skin and nail disease) [1, 2],
which has significant impact on health-related quality of life
(HRQoL) and disability [3]. Of these, enthesitis is a clinical,
periarticular manifestation seen both at early and late phases
of the disease [4–6] which can differentiate PsA from
rheumatoid arthritis [2, 7]. Enthesitis is defined as inflamma-
tion of tendon, ligament, or joint capsule insertion sites to
bone and may be important in PsA development [2, 8].
Entheses are anatomically, functionally, and physiologically
associated with synovia and form the “synovio-entheseal
complex” which are comprised of soft and hard tissue. The
enthesis organ dissipates stress, which may be a poten-
tial triggering mechanism of enthesitis and, ultimately,
PsA [5, 9, 10]. About 30–50% of patients with PsA suf-
fer from enthesitis based on standard clinical examination,
which may, however, underestimate or misinterpret such
symptoms [8], since imaging studies have revealed the
prevalence rate to be as high as 70% [11].
Type 3 innate lymphoid cells and γ T cells are
present at entheseal sites which on activation stimulate
the production of interleukin (IL)-17 [4, 12]. The IL-17
pathway augments the influx and activation of neutro-
phils which are the effector cells of entheseal inflamma-
tion, and stimulates the release of proteases and reactive
oxygen species that lead to pain response during enthe-
seal inflammation [4, 8].
Enthesitis is frequently associated with increased pain,
fatigue, physical disability, structural damage, and reduced
work productivity compared to patients without enthesitis
[13, 14]. According to the Group for Research and Assess-
ment of Psoriasis and Psoriatic Arthritis (GRAPPA),
enthesitis reflects higher disease burden and represents
one of the six clinical core domains requiring diagnosis,
assessment, and treatment in PsA [1, 15]. The recently up-
dated American College of Rheumatology/National Psor-
iasis Foundation guideline has recommended treatment
with IL-17 or IL-12/23 inhibitor in PsA patients with pre-
dominant enthesitis who have severe psoriasis or contrain-
dications to first-line treatment with tumor necrosis factor
inhibitors (TNFi) [16].
Secukinumab, a fully human, monoclonal IgG1κ antibody
that directly inhibits IL-17A, has been shown to provide sig-
nificant and sustained improvement in the different facets of
active PsA [17–20]. In the FUTURE 2 and FUTURE 3 stud-
ies, secukinumab demonstrated early and sustained clinical
efficacy in PsA patients up to 4 years [18–21]. Secukinumab
300 and 150mg provided rapid and sustained resolution of
enthesitis in ~ 70% of patients with enthesitis at baseline
through 4 years in FUTURE 2 [18, 19, 21] and in ~ 50% pa-
tients through 1 year in FUTURE 3 [20].
Herein, we present a comprehensive post hoc analysis
using pooled data from the FUTURE 2 and FUTURE 3
studies over 2 years, to further evaluate the effect of
secukinumab on (a) enthesitis count (EC; defined by the
Leeds Enthesitis Index [LEI]), (b) time to resolution of
enthesitis, (c) shift in baseline EC (1, 2, or 3–6) to reso-
lution, and (d) the occurrence of enthesitis in patients
with no enthesitis at baseline. We also evaluated if clin-
ical outcomes were similarly improved with secukinu-
mab irrespective of the presence of enthesitis at baseline.
Methods
Study design and patients
FUTURE 2 (NCT01752634) is a 5-year and FUTURE 3
(NCT01989468) a 3-year, randomized, double blind,
placebo-controlled phase 3 study [18, 20]. Details of the
study designs and inclusion and exclusion criteria are
reported elsewhere [18, 20]. Briefly, patients aged ≥ 18
years who met the ClASsification criteria for Psoriatic
ARthritis (CASPAR) and had active disease (defined as
at least three tender joints and at least three swollen
joints) with inadequate response/intolerance to non-
steroidal anti-inflammatory drugs (NSAIDs), disease-
modifying anti-rheumatic drugs (DMARDs), or up to
three TNFi agents were included. Key exclusion criteria
were as follows: prior use of any biologics other than
TNFi, active inflammatory diseases other than PsA, ac-
tive infection in the 2 weeks before randomization, evi-
dence of tuberculosis, and history of malignant disease
within the past 5 years.
FUTURE 2 comprised 397 patients with active PsA who
were randomized (1:1:1:1) to receive s.c. secukinumab
300, 150, or 75mg or placebo at baseline; weeks 1, 2, 3,
and 4; and once every 4 weeks thereafter. Placebo-treated
patients were re-randomized to receive s.c. secukinumab
300 or 150mg either at week 16 (non-responders with <
20% improvement from baseline in tender and swollen
joint counts) or week 24 (responders with ≥ 20% improve-
ment). In FUTURE 3, 414 patients with active PsA were
randomized (1:1:1) to receive self-administered s.c. secuki-
numab 300, 150mg, or placebo at baseline; weeks 1, 2, 3,
and 4; and every 4 weeks thereafter. Placebo-treated pa-
tients were re-randomized to s.c. secukinumab 300 or 150
mg either at week 16 (non-responders) or 24 (responders).
In this post hoc analysis, data were pooled from the FU-
TURE 2 and FUTURE 3 studies based on the presence or
absence of clinical enthesitis (as defined by the LEI) at
baseline.
The studies were conducted in compliance with the
Declaration of Helsinki [22], International Council for
Harmonization Guidelines for Good Clinical Practice,
and local country regulations. The studies were ap-
proved by institutional review boards or independent
ethics committees at each participating center. Written
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informed consent was obtained from all enrolled pa-
tients. Data were collected in accordance with Good
Clinical Practice guidelines by the study investigators
and were analyzed by the sponsor. The baseline demo-
graphics and clinical characteristics were compared in
patients with and without enthesitis at baseline.
Assessments
Leeds Enthesitis Index
In this post hoc analysis, patients were grouped based on
the presence or absence of enthesitis at baseline as defined
by the LEI, a validated instrument that uses six sites for
evaluation of enthesitis (left and right sides): lateral epi-
condyles of the humerus, Achilles tendon insertions, and
medial femoral condyles. The LEI is a reliable index show-
ing good correlation with other enthesitis indices of PsA
and can distinguish between patients with and without ac-
tive enthesitis [8, 23, 24]. Tenderness on examination was
recorded as either present (1) or absent (0) at each of the
six sites, for an overall score range of 0–6 with higher
scores indicating greater enthesitis burden. If enthesitis
was present at any of the six sites at baseline, the patient
was counted as a patient with enthesitis [23].
Resolution and time to first resolution of enthesitis
Among patients with enthesitis at baseline, the Kaplan-
Meϊer analyses were employed (1) to calculate the propor-
tion of patients with resolution of enthesitis at weeks 16, 52,
and 104 and (2) to estimate the median time to first reso-
lution of enthesitis (i.e., first assessment time with EC= 0).
Shift analysis of EC from baseline to weeks 24, 52, and 104
Shift analysis was performed to analyze the resolution of
enthesitis at weeks 24, 52, and 104 based on severity of
enthesitis categories at baseline, i.e., mild, EC = 1; moderate,
EC = 2; or severe, EC = 3–6. There were three mutually ex-
clusive resolution criteria in this analysis: full resolution
(EC = 0), stable including those with EC partly improved
(0 < EC ≤ baseline EC), and worse (EC > baseline EC).
Heat map analysis
Individual patient status of resolution of EC through
week 104 by treatment arms was visualized using heat
map analysis. All patients with enthesitis at baseline
were followed until the end of study or discontinuation.
Red shading was used for EC ≥ baseline, yellow shading
for partial resolution with an EC < baseline, and green
shading for full resolution with an EC = 0.
New enthesitis sites in patients without enthesitis at
baseline
In patients without enthesitis at baseline, the number
of sites developing new enthesitis (ES) was assessed
through week 104.
Relationship between baseline enthesitis status and
outcomes across multiple clinical domains
The relationship between the presence or absence of
enthesitis and different efficacy outcomes was analyzed in
patients with or without enthesitis at baseline after adjust-
ing for confounding baseline characteristics at weeks 16
and 104. The efficacy outcomes included the following:
proportion of patients achieving American College of
Rheumatology (ACR) 20, 50, and 70 response rates; Psor-
iasis Area and Severity Index (PASI) 75 and 90 response
rates; and mean change from baseline in Health Assess-
ment Questionnaire Disability Index (HAQ-DI), Short
Form 36 Physical Component Summary score (SF-36
PCS), and 28-Joint Disease Activity Score using C-reactive
protein (DAS28-CRP). Unadjusted analyses were also per-
formed in patients with or without enthesitis.
Statistical analysis
Data are presented for secukinumab 300 and 150 mg
(approved doses) up to week 104, and for placebo only
up to week 16/24 (i.e., at weeks 52 and 104, data were
analyzed only for patients originally randomized to secu-
kinumab). The analysis on resolution and time to first
resolution of enthesitis was done in the overall popula-
tion, as well as split into TNFi-naïve and TNFi-IR (pa-
tients with an inadequate response or intolerance with
prior use of up to three TNFi) subgroups. The Kaplan-
Meϊer estimate accounted for censoring, dropouts, and
loss to follow-up. Patients randomized to the secukinu-
mab arms were followed until their last visit or loss to
follow-up while patients in the placebo arm were cen-
sored at 168 days (24 weeks) of follow-up. The Y-axis on
the Kaplan-Meϊer figures represent the survival function,
which was defined as the proportion (%) of patients who
had not yet experienced resolution at the particular time
on the X-axis, after accounting for dropouts and censor-
ing. The survival function was calculated using the
product-limit formula, which was the proportion (%) of
patients who had not yet experienced resolution at a
particular time multiplied by the percentage at all previ-
ous times when enthesitis occurred. The percentage of
patients with resolution at weeks 16, 52, and 104 were
computed as 1 minus the survival function estimates at
days 112, 365, and 729, respectively. The shift analysis
on EC was performed from baseline to weeks 24, 52,
and 104 according to EC severity at baseline (1, 2, 3–6)
using as observed analysis in patients with data available
at both visits.
Heat map analysis used the last observation carried
forward (LOCF) to impute status between scheduled
visits with available data at baseline and weeks 8, 16, 24,
52, and 104.
Clinical and patient-reported outcomes were evaluated
by enthesitis status at baseline and at weeks 16 (all
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treatment groups) and 104 (secukinumab groups only)
using as observed data. To adjust for potential con-
founding variables, logistic regression and analysis of
covariance (ANCOVA) were employed to analyze binary
and continuous variables, respectively. In each model,
independent variables included treatment group, enthe-
sitis status at baseline, gender, DAS28-CRP at baseline,
HAQ-DI at baseline, prior TNFi status, and the inter-
action between treatment group and enthesitis status at
baseline.
Results
Demographic and baseline disease characteristics
A total of 712 patients were included in this pooled ana-
lysis, of which 466 (65%) patients were diagnosed with
enthesitis at baseline (secukinumab 300 mg, 144/239;
150 mg, 159/238; and placebo, 163/235). Demographics
were generally comparable across groups except for a
slightly higher proportion of females among the patients
with baseline enthesitis. The mean time since first diag-
nosis of PsA in the pooled analysis was > 6 years in both
the enthesitis and without enthesitis groups. Around
two thirds of patients were naïve to TNFi therapy. On
average, patients with enthesitis displayed three tender
entheses at baseline and the mean EC was comparable
between the secukinumab (3.0 and 3.2 with 300 and 150
mg, respectively) and placebo groups (3.0). The enthesitis
group had more active disease at baseline, as reflected by
numerically higher tender and swollen joint counts, pa-
tient and physician global assessment scores, DAS28-CRP,
and HAQ-DI scores than patients without enthesitis
(Table 1).
Resolution of EC in patients with enthesitis at baseline
The Kaplan-Meϊer analysis showed that 65%, 56%, and
44% of patients in the overall population treated with
secukinumab 300, 150 mg, and placebo, respectively,
achieved full resolution of EC at week 16. This further
improved to 91% and 88% with secukinumab 300 mg
and 150 mg, respectively, at week 104 (Fig. 1). The mag-
nitude of response was higher with secukinumab 300 mg
than 150 mg. A high proportion of secukinumab treated
patients achieved resolution of EC in both TNFi-naïve
(300 mg and 150 mg, 72% and 57% vs 47% placebo [week
16]; 93% and 92% week 104]) and TNFi-IR patients (300
mg and 150 mg, 50% and 54% vs 40% placebo [week 16];
87% and 84% [week 104]), with numerically higher re-
sponses in TNFi-naïve than TNFi-IR patients (Fig. 1).
Time to first resolution of enthesitis
The Kaplan-Meϊer plots of time to first resolution of enthe-
sitis were presented for the overall population and split into
TNFi-naïve and TNFi-IR subgroups (Fig. 2). The median
days to resolution of EC in patients with enthesitis at
Table 1 Demographics and baseline characteristics of patients with and without enthesitis at baseline
Characteristic With enthesitis at baseline Without enthesitis at baseline
Secukinumab Placebo (N = 163) Secukinumab Placebo (N = 72)
300 mg (N = 144) 150 mg (N = 159) 300 mg (N = 95) 150 mg (N = 79)
Age (years), mean (SD) 48.3 (12.5) 48.0 (11.8) 48.9 (13.3) 46.5 (13.7) 48.7 (12.8) 50.4 (11.9)
Female, % 55 53 69 44 48 33
Weight (kg), mean (SD) 88.1 (21.0) 90.8 (19.4) 82.9 (18.9) 83.8 (15.1) 84.1 (17.8) 85.3 (16.4)
Caucasian, % 95 93 97 96 92 96
TNFi-naïve, % 68 63 64 67 72 72
Time since first diagnosis
of PsA (years), mean (SD)
7.7 (8.7) 7.4 (8.8) 6.8 (7.0) 8.2 (8.4) 6.7 (7.6) 7.1 (8.0)
Number of enthesitis sites,
mean (SD)
3.0 (1.7) 3.2 (1.7) 3.0 (1.6) 0 0 0
Tender joint total score
(78 joints), mean (SD)*
23.5 (15.6) 27.0 (19.8) 26.3 (18.4) 14.6 (9.6) 16.9 (13.6) 14.1 (11.2)
Swollen joint total score
(76 joints), mean (SD)*
10.3 (6.9) 12.2 (10.1) 12.1 (10.3) 9.3 (7.4) 10.0 (8.1) 8.6 (7.1)
DAS28-CRP, mean (SD) 4.8 (1.0) 4.9 (1.1) 4.9 (1.1) 4.3 (1.0) 4.4 (1.1) 4.3 (0.9)
HAQ-DI, mean (SD) 1.3 (0.7) 1.2 (0.6) 1.3 (0.6) 1.0 (0.6) 1.2 (0.6) 1.1 (0.7)
Patient global assessment,
mean (SD)
N = 142, 62.6 (18.7) N = 156, 61.6 (21.6) N = 161, 62.2 (20.1) N = 95, 56.6 (21.5) N = 79, 59.1 (19.9) N = 72, 53.1 (19.9)
Physician global assessment,
mean (SD)
N = 143, 54.4 (18.3) N = 158, 57.0 (16.4) N = 163, 57.1 (15.7) N = 94, 51.0 (16.8) N = 79, 53.6 (17.0) N = 72, 49.9 (19.4)
DAS28-CRP 28-Joint Disease Activity Score count using C-reactive protein, HAQ-DI Health Assessment Questionnaire Disability Index, PsA psoriatic arthritis, SD
standard deviation, TNF tumor necrosis factor
*In case of joints for which the data was not available, the observed count of the joints was scaled up proportionately
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baseline were shorter with secukinumab than placebo in
the overall population (secukinumab 300 and 150mg vs
placebo, 57 and 85 vs 167 days), TNFi-naïve patients (57
and 85 vs 120 days), and TNFi-IR patients (92 and 82 vs
169 days) (Fig. 2), with resolution being faster in patients
treated with secukinumab 300mg versus 150mg in the
overall population and TNFi-naïve patients.
Shift analysis in EC from baseline to weeks 24, 52, and 104
In patients with EC= 1 at baseline, 72% (secukinumab 300
mg), 71% (secukinumab 150mg), and 45% (placebo), respect-
ively, achieved full resolution at week 24, which increased to
77% (secukinumab 300mg) and 75% (secukinumab 150mg)
at week 104 (Fig. 3). Similarly, in patients with EC= 2 at
baseline, the response rates for full resolution at week 24
(61% [300mg], 66% [150mg] vs 44% [placebo]) further im-
proved at week 104 (81% and 88% with secukinumab 300
mg and 150mg, respectively). In contrast, in patients with se-
vere enthesitis at baseline (EC= 3–6), no difference was seen
in terms of full resolution between secukinumab 300mg,
150mg, and placebo (37%, 40% vs 37%) at week 24. By weeks
52 and 104, 47% and 61% (secukinumab 300mg) and 47%
and 50% (secukinumab 150mg) of patients with EC= 3–6 at
baseline had attained full resolution, respectively (Fig. 3).
Fig. 1 Proportion of patients with enthesitis at baseline achieving full resolution over 104 weeks. Data shown for overall population (A), TNFi-
naïve (B), and TNFi-IR (C) subpopulations. n, number of patients with enthesitis at baseline. Proportion of patients with resolution at weeks 16, 52,
and 104 were based on the survival analysis (Kaplan-Meϊer estimates) at days 112, 365, and 729, respectively. Placebo patients were censored at
day 168 of follow-up. EC, enthesitis count; FR, full resolution; IR, inadequate responder; SEC, secukinumab; TNFi, tumor necrosis factor inhibitor
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Heat map analysis
Heat map analysis showed that secukinumab-treated pa-
tients at individual levels had more resolution of EC
than placebo patients at week 24, which was sustained
through week 104 (Fig. 4).
Development of enthesitis in patients without enthesitis
at baseline
The majority of patients without enthesitis at baseline
did not develop enthesitis at week 16 (86%, 95%, and
83% in the secukinumab 300 mg, 150 mg, and placebo
Fig. 2 Time to resolution of enthesitis in patients with enthesitis at baseline. Data shown for overall population (A), TNFi-naïve (B), and TNFi-IR (C)
subpopulations. Percentages of patients with resolution at weeks 16, 52, and 104 were derived as 1 minus the survival function at days 112, 365,
and 729, respectively (Kaplan-Meϊer plot). Placebo patients were censored at day 168 of follow-up. IR, inadequate responder; SEC, secukinumab;
TNFi, tumor necrosis factor inhibitor
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Fig. 3 Shift analysis of enthesitis count from baseline to weeks 24, 52, and 104. A, B, and C represents EC = 1, 2, and 3–6 at baseline, respectively.
EC 3–6 group includes patients with baseline EC 3, 4, 5, or 6. Shift analysis on resolution of EC from baseline to week 24/52/104 is categorized
based on the three criteria of resolution: FR (EC = 0), stable (0 < EC ≤ baseline EC), and worse (> baseline EC). EC, enthesitis count; FR, full
resolution; n, number of patients who completed week 24 and had EC available at both baseline and week 24
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groups, respectively), which was maintained at week 104
(89% with both secukinumab 300 mg and 150 mg)
(Fig. 5).
Relationship between enthesitis status and outcomes
across multiple clinical domains
At week 16, patients with enthesitis at baseline treated
with secukinumab 300 and 150mg showed better out-
comes compared with placebo for ACR20 (51.6% and
44.3% vs 19.5%, respectively), ACR50 (31.4% and 21.0%
vs 7.5%), PASI 90 (66.5% and 51.8% vs 13.1%), DAS28-
CRP (− 1.4 and − 1.0 vs − 0.5), HAQ-DI (− 0.5 and − 0.3
vs − 0.2), and SF-36 PCS (6.1 and 3.5 vs 2.3). Improve-
ments were generally greater with secukinumab 300 mg
than 150 mg for all efficacy outcomes (Table 2). In pa-
tients without enthesitis at baseline, secukinumab 300
and 150 mg again showed higher responses than placebo
for ACR20 (48.8% and 60.4% vs 13.8%), ACR50 (32.6%
and 32.9% vs 4.1%), and PASI 90 (56.4% and 48.9% vs
10.8%), with reduced disease activity (DAS28-CRP − 1.3
and − 1.5 vs − 0.4) and improved physical function and
HRQoL (HAQ-DI − 0.4 and − 0.5 vs − 0.2; SF-36 PCS
6.1 and 7.0 vs 2.0) (Table 2). The improvements with
secukinumab 300 and 150mg were sustained or further
improved over 104 weeks for most outcome measures in
patients with and without enthesitis (Table 2). Un-
adjusted analysis showed similar trends for improved
and sustained efficacy outcomes until week 104 in
secukinumab-treated patients (Additional file 1: Table
S1).
Discussion
The current knowledge on the treatment of enthesitis is
limited. Most randomized, controlled trials in PsA focus
on polyarticular disease, which accounts only for a sub-
group of PsA. To date, no randomized, controlled study
has been specifically designed to evaluate the treatment
of enthesitis. Notably, most clinical trials in which enthe-
sitis indices were applied to assess enthesitis outcomes
among patients displaying this symptom at baseline were
not adequately powered to assess enthesitis [25–28].
The objectives of this pooled analysis from the FU-
TURE 2 and FUTURE 3 studies were to describe the
demographics and clinical characteristics of the patients
Fig. 4 Heat map of enthesitis resolution by treatment group through week 104. The asterisk indicate discontinuation due to following reasons:
adverse events, death, lack of efficacy, lost to follow-up, non-compliance with study treatment, physician decision, pregnancy, patient/guardian
decision, and withdrawal of informed consent. Placebo patients switched therapies at week 16 or 24. All patients with enthesitis at baseline were
followed until the end of study or discontinuation. BL, baseline, EC, enthesitis count; W, week
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Fig. 5 Change in enthesitis sites with secukinumab 300 mg and 150 mg over week 104 in patients with no enthesitis at baseline. Data presented
are as observed. Number of evaluable patients at week 4—90 (300 mg), 78 (150mg), and 70 (placebo); at week 16—92 (300 mg), 78 (150 mg),
and 70 (placebo); and at week 104—83 (300mg) and 62 (150 mg). ES, enthesitis site; n, number of patients with no enthesitis at weeks 4, 16,
and 104
Table 2 Adjusted efficacy outcome measures in patients with or without enthesitis at baseline
Outcome
measures
Week With enthesitis at baseline Without enthesitis at baseline
Secukinumab Placebo
(N =
163)
Secukinumab Placebo
(N = 72)300 mg (N = 144) 150 mg (N = 159) 300 mg (N = 95) 150 mg (N = 79)
ACR20a,b 16 51.6 44.3 19.5 48.8 60.4 13.8
104 55.2 59.1 – 57.6 59.8 –
ACR50a,b 16 31.4 21.0 7.5 32.6 32.9 4.1
104 43.4 25.7 – 43.5 28.9 –
ACR70a,b 16 20.5 10.7 2.9 23.4 18.5 1.4
104 26.7 17.0 – 32.8 18.9 –
PASI 90a,c 16 66.5 51.8 13.1 56.4 48.9 10.8
104 46.2 34.9 – 52.5 24.8 –
PASI 75a,c 16 82.3 62.0 10.6 68.1 59.8 7.3
104 88.5 87.4 – 95.5 80.1 –
HAQ-DId 16 − 0.5 − 0.3 − 0.2 − 0.4 − 0.5 − 0.2
104 − 0.4 − 0.3 – − 0.5 − 0.5 –
SF-36 PCSd 16 6.1 3.5 2.3 6.1 7.0 2.0
104 6.9 4.0 – 6.3 6.0 –
DAS28-CRPd 16 − 1.4 − 1.0 − 0.5 − 1.3 − 1.5 − 0.4
104 − 1.7 − 1.5 – − 1.9 − 1.7 –
Logistic regression (for binary variables) or ANCOVA (for continuous variables) were performed as a function of the patient characteristics at baseline (treatment
group, enthesitis status, gender, DAS28-CRP, HAQ-DI, TNFi-status), and the interaction between treatment groups and enthesitis status
ACR American College of Rheumatology, DAS28-CRP; 28-Joint Disease Activity Score count using C-reactive protein, HAQ-DI Health Assessment Questionnaire
Disability Index, LS least square, n number of evaluable patients, N total number of patients, PASI Psoriasis Area and Severity Index, SF-36 PCS Short Form 36
Physical Component Summary score
aResponse, %
bAt week 16/104, n = 144/132 (secukinumab 300mg), 159/145 (secukinumab 150 mg), and 163 (placebo) with enthesitis and n = 95/91 (secukinumab 300mg), 79/
70 (secukinumab 150 mg), and 72 (placebo) without enthesitis at baseline
cAt week 16/104, n = 66/56 (secukinumab 300 mg), 82/62 (secukinumab 150mg), and 63 (placebo) with enthesitis and n = 38/34 (secukinumab 300 mg), 46/36
(secukinumab 150mg), and 30 (placebo) without enthesitis at baseline (psoriasis subset)
dLS mean change from baseline
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who had both polyarticular disease as per inclusion cri-
teria and baseline enthesitis, and to assess the efficacy of
secukinumab on resolution of enthesitis in patients with
PsA over 2 years. The present analysis showed that the
65% of PsA patients who were diagnosed with enthesitis
at baseline had more severe disease activity and reduced
physical function compared with patients without enthe-
sitis. This is consistent with data from the Corrona
registry in PsA showing a higher disease activity, a
poorer functional status, a worse quality of life, and
greater patient-reported pain and fatigue in patients with
enthesitis compared to those without enthesitis [13].
Enthesitis, therefore, is an important clinical domain of
PsA that serves as an indicator of disease severity and
high disease burden.
Clinically, enthesitis is invariably perceived as tenderness
at entheses with entheseal swelling being uncommon. Dif-
ferent indices have been developed to help assess and
measure enthesitis. The most commonly used indices for
the assessment of enthesitis include the Spondyloarthritis
Research Consortium of Canada (SPARCC), Maastricht
ankylosing spondylitis enthesitis score (MASES), and LEI
[24], which are clinically validated, reliable, and sensitive to
change. The LEI and SPARCC are more specific for enthe-
sitis in PsA, examining 6 and 16 sites of enthesitis, respect-
ively. The LEI is easy to perform, and when compared with
MASES, SPARCC, and Berlin indices, LEI correlates most
consistently with the clinical parameters of disease activity
in patients with PsA [24, 29]. Furthermore, LEI is capable
of distinguishing between patients with and without active
PsA [23]. In the present analysis, we used the clinical reso-
lution of enthesitis (EC = 0) which is a very stringent out-
come in contrast with the LEI change from baseline used
in most PsA clinical trials with TNFi [27, 28, 30]. TNFi
were shown to improve peripheral enthesitis as assessed by
clinical indices of enthesitis in PsA [25–27, 30]. However,
little is known on the median time to resolve enthesitis,
and the magnitude of response by enthesitis severity, by
time since diagnosis, or after switch to other TNF inhibi-
tors [27, 28, 30] as well as development of enthesitis over
time in patients with no enthesitis at baseline.
In the overall population, patients with enthesitis at
baseline treated with secukinumab showed higher rates
of full resolution of enthesitis compared with placebo at
week 16, which further improved at week 104. The mag-
nitude of response was higher in patients treated with
secukinumab 300 than 150 mg. Similarly, secukinumab
showed early and sustained resolution of enthesitis in
TNFi-naïve and TNFi-IR patients through 2 years, with
higher response in TNFi-naïve than TNFi-IR patients.
Resolution of enthesitis data from this pooled analysis
are in line with previously reported enthesitis data from
the FUTURE 5 trial where an early and sustained reso-
lution was observed up to 2 years (week 24, 61.4% [P <
0.0001] and 54.6% [P < 0.001] with secukinumab 300 and
150 mg, respectively, vs 34.4% with placebo; week 104,
78% and 80.3% with secukinumab 300 and 150 mg, re-
spectively) [31, 32].
These post hoc analyses illustrate for the first time in
the literature the kinetics of enthesitis response to a bio-
logic treatment as assessed by time to resolution of
enthesitis, complemented with a shift analysis from base-
line to weeks 24, 52, or 104, and heat map analysis.
Secukinumab provided faster resolution of enthesitis
compared with placebo in the overall population, as well
as in both TNFi-naïve and TNFi-IR patients, with faster
response in TNFi-naïve than TNFi-IR patients. These
data are encouraging because enthesitis is known to be
very painful and limiting, and can last for prolonged pe-
riods if not treated appropriately. Although full reso-
lution took longer time in the more refractory TNFi-IR
patients, the median time for achieving complete reso-
lution was within the first 3 months. Secukinumab 300
mg showed faster resolution compared with 150 mg in
the overall population and TNFi-naïve patients.
The shift analysis of enthesitis from baseline to week
24 by degree of severity of EC at baseline showed higher
rate of full resolution in patients with mild to moderate
enthesitis (EC = 1 or 2) with secukinumab 150 and 300
mg than placebo at week 24, with increased resolution at
weeks 52 and 104. In contrast, no difference in full reso-
lution of enthesitis was observed at week 24 between
placebo and secukinumab 150 or 300 mg in patients with
EC of 3–6 and proportions of patients from this group
who had full resolution at weeks 52 and 104 were lower
than in patients with less severe enthesitis. This high-
lights that achievement of full resolution in patients with
more severe disease takes longer time and is more diffi-
cult to achieve. Heat map analysis helped visualizing EC
resolution at individual level and extends the findings of
the shift analysis by visually showing that from week 24
to 104, most patients treated with secukinumab sustain
resolution of enthesitis.
The majority of patients without baseline enthesitis
(89%) did not develop enthesitis over 2 years of treat-
ment with secukinumab 300 or 150 mg. This supports
the hypothesis that IL-17A inhibition may prevent the
development of new enthesitis sites as well as providing
sustained resolution of enthesitis in patients with base-
line enthesitis.
TNFi studies have indicated that PsA patients with
enthesitis are a difficult-to-treat population with a lower
odds of achieving minimal disease activity (MDA) com-
pared to patients without enthesitis [33]. Indeed, the ab-
sence of enthesitis is a predictor of MDA in patients
treated with TNFi [34]. In contrast, secukinumab-treated
patients with PsA showed higher ACR and PASI re-
sponses, reduced disease activity, and improved physical
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function and HRQoL versus placebo, regardless of enthesi-
tis status at baseline. A greater magnitude of improvement
in signs and symptoms, physical function, and quality of life
was observed in patients with enthesitis at baseline treated
with secukinumab 300mg than with 150mg. Importantly,
the response rates in patients with and without enthesitis at
baseline indicate that secukinumab 300mg showed similar
efficacy on different composite endpoints in both popula-
tions. This is in line with a pooled efficacy analysis from
FUTURE 2–5 using machine learning which showed a
greater response with secukinumab 300mg over 150mg in
patients with baseline enthesitis [35]. These improvements
reported across all endpoints were sustained or further
increased over 104 weeks of secukinumab treatment,
which were consistent with the FUTURE 1 and 5 stud-
ies [17, 31, 32].
The GRAPPA recommendations issued in 2016 men-
tioned non-steroidal anti-inflammatory drugs and physio-
therapy as initial treatment and TNFi as the first-line
biologics for enthesitis in PsA patients [1]. Limited enthe-
sitis data with secukinumab were available when the
GRAPPA recommendations were issued. Data from TNFi
studies are difficult to compare with the present pooled
analysis as they used either LEI change from baseline or
different scoring systems such as MASES and SPARCC
[27, 36]. A head-to-head trial comparing secukinumab
and adalimumab, which includes the assessment of
enthesitis as a key secondary endpoint, will be reported
in the future (NCT02745080). In another head-to-head
trial of an IL-17 inhibitor (ixekizumab) versus adalimu-
mab (SPIRIT-P1), ixekizumab showed higher resolution
of enthesitis (as measured by LEI) than adalimumab at
week 24 (ixekizumab 80 mg once every 4 weeks, 43%,
and ixekizumab 80 mg once every 2 weeks, 39%, vs ada-
limumab, 33%) [37]. The recently published pooled data
from the SPIRIT-P1 and SPIRIT-P2 studies with ixeki-
zumab showed significant resolution of enthesitis at
week 24 versus placebo (ixekizumab 80 mg once every
4 weeks, 39%, and ixekizumab 80 mg once every 2
weeks, 35%, vs placebo, 21%) [38]. Data from the FU-
TURE studies [19, 20, 32] along with this pooled ana-
lysis provide comprehensive evidence supporting the
efficacy of secukinumab on enthesitis in PsA patients.
The potential limitations of the current analysis in-
clude its post hoc nature. Clinical enthesitis was not an
inclusion criteria in the FUTURE studies. EC by use of
the LEI (with only six sites) entails a probability of miss-
ing peripheral enthesitis at other sites. Scoring of enthe-
sitis in the medial femoral condyle may be difficult
because of joint swelling. Clinical indices such as LEI
may not be specific, especially when there is overlap with
fibromyalgia, mechanical injury, or tendinitis. Power
Doppler Ultrasound was not performed at baseline to
confirm the clinical assessment of enthesitis, and X-ray
did not evaluate the impact on structural damage at
baseline and up to 2 years. Another limitation is that the
observed data analyses do not account for dropouts or
missing data. There was no placebo group beyond weeks
16/24, and given the post hoc nature of this study, only
numerical but no statistical comparisons were done be-
tween treatment groups. No additional analysis was done
to assess the frequency of each enthesitis site at baseline
and if any of them was more sensitive to treatment. The
impact of secukinumab on resolution of enthesitis using
imaging will be assessed in two multicenter, randomized,
placebo-controlled trials which are currently ongoing:
(1) the ULTIMATE study (NCT02662985) will use ultra-
sound to demonstrate the time course of response to
secukinumab of enthesitis in biologic naïve PsA patients;
(2) the ACHILLES study (NCT02771210) will use mag-
netic resonance imaging to evaluate the efficacy of secu-
kinumab on resolving Achilles tendon enthesitis in
patients with active PsA and axial spondyloarthritis
despite current or previous NSAID, DMARD, or TNFi
exposure.
Conclusion
This post hoc analysis further extends the evidence for
an early and sustained efficacy of secukinumab on
enthesitis in patients with PsA irrespective of previous
TNFi exposure. Secukinumab 300 mg was associated
with greater efficacy on enthesitis than 150 mg notably
in patients with higher baseline EC. Although patients
with enthesitis at baseline had higher disease activity,
secukinumab improved outcomes across multiple clin-
ical domains of PsA as early as week 16 and maintained
efficacy over 2 years, with responses being similar to pa-
tients without enthesitis, especially with the secukinu-
mab 300 mg dose.
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